Current concepts regarding pharmacologic treatment of rheumatoid and osteoarthritis

Hand Clinics

Volumn 17, Issue 2, 2001, Pages 321-338

  Wildy, K S ^a   Wasko, M C M ^a  

^a Division of Rheumatology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTRON; ANTIRHEUMATIC AGENT; ARACHIDONIC ACID; AZATHIOPRINE; CAPSAICIN; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DICLOFENAC; DICLOFENAC POTASSIUM; ETANERCEPT; ETODOLAC; FLURBIPROFEN; GLUCOCORTICOID; GLUCOSAMINE SULFATE; HYALURONIC ACID; HYDROXYCHLOROQUINE; IBUPROFEN; INDOMETACIN; INFLIXIMAB; KETOPROFEN; LEFLUNOMIDE; LEUKOTRIENE; MELOXICAM; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE A2; PIROXICAM; ROFECOXIB; SALAZOSULFAPYRIDINE; THROMBOXANE A2;

ABDOMINAL PAIN; ALOPECIA; ANALGESIA; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DYSPEPSIA; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; HEADACHE; HUMAN; NAUSEA AND VOMITING; OSTEOARTHRITIS; PROTEIN EXPRESSION; RASH; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYCLOOXYGENASE INHIBITORS; DIGESTIVE SYSTEM; GLUCOCORTICOIDS; HUMANS; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G; ISOXAZOLES; LACTONES; METHOTREXATE; OSTEOARTHRITIS; PYRAZOLES; RECEPTORS, TUMOR NECROSIS FACTOR; SULFASALAZINE; SULFONAMIDES; SULFONES;

EID: 0034943888     PISSN: 07490712     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. The mechanisms of action of nonsteroidal anti-inflammtory drugs
2. Management of corticosteroid-induced osteoporosis
3. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor in rheumatoid arthritis
4. Gene therapy of collagen-induced arthritis
5. In-vitro evaluation of drugs proposed as chondroprotective agents
6. Chondroitin suflate: Its in vitro effects on human articular chondrocytes cultivated in clusters
7. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial
8. Ocular safety of hydroxychloroquine
9. Comparison of an inflammatory dose of ibuprofen, an analgesic doses of ibuprofen and acetaminophen in the treatment of patients with osteoarthritis of the knee
10. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors
11. Nonsteroidal antiinflammatory drugs: Differences and similarities
12. Hydroxychloroquine compared with placebo in rheumatoid arthritis: A randomized controlled trial
13. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors
14. The anti-inflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation
15. Treatment with recombinant human interleukin-1 receptor antagonist may reduce synovial infiltration in rheumatoid arthritis
16. Sulfasalazine
17. Treatment of arthritis with topical capsaicin: A double-blind trial
18. Glucosamine in the treatment of osteoarthritis
19. Combination therapy in early rheumatoid arthritis: A randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components
20. Effect of specific COX-2 inhibition in osteoarthritis of the knee: A 6 week double blind, placebo controlled pilot study of rofecoxib
21. Repeated therapy with monoclonal antibody to tumour necrosis factor-α (cA2) in patients with rheumatoid arthritis
22. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
23. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis: A metaanalysis of published clinical trials
24. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: Results of two meta-analyses
25. Mechanism of action of leflunomide in rheumatoid arthritis
26. Cigarettes, alcohol, coffee, and peptic ulcer
27. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies
28. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury
29. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis
30. Methotrexate in rheumatoid arthritis
31. Corticosteroid-induced suppression of the hypothalamo-pituitary-adrenal axis: Observation on patients given oral corticosteroids for rheumatoid arthritis
32. The effect of glucocorticoids on joint destruction in rheumatoid arthritis
33. Glucocorticoid-induced adrenal insufficiency
34. Methotrexate and leflunomide: Biochemical basis for combination therapy in the treatment of rheumatoid arthritis
35. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase-2-specific inhibtor with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
36. A review of gastric ulcer and gastroduodenal injury in normal volunteers receiving aspirin and other non-steroidal anti-inflammatory drugs
37. Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract: The double-edged sword
38. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor-alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
39. Infliximab (chimeric anti-tumour necrosis factor α-monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
40. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
41. Long-term effects of glucosamine sulfate on osteoarthritis progression: A randomized, placebo-controlled clinical trial
42. Nonsteroidal anti-inflammatory drug-related gastrointestinal toxicity: Definitions and epidemiology
43. The use of analgesics in the management of pain in rheumatic diseases
44. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
45. Etanercept therapy in rheumatoid arthritis
46. Methotrexate use in rheumatoid arthritis
47. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications
48. Leflunomide for the treatment of rheumatoid arthritis
49. Differential inhibition of cyclooxygenase activity of prostaglandin endoperoxide synthase isozymes in vitro and ex vivo in pan
50. New highly selective COX-2 inhibitors
51. Topical capsaicin. A review of its pharmacological properties and therapeutic potential in post-hepetic nueralgia, diabetic neuropathy and osteoarthritis
52. Sulfasalazine: A review of its pharmacological properties and therapeutic efficacy in the treatment of rhematoid arthritis
53. Course and prognosis of early rheumatoid arthritis
54. Duodenal-ulcer disease associated with elevated serum pepsinogen: I. An inherited autosomal dominant disorder
55. MK-0966, a specific XOX-2 inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteorthritis (OA) in a 6-week controlled clinical trial
56. Perioperative glucocorticoid coverage: A reassessment 42 years after emergence of a problem
57. The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone
58. Tramadol allows reduction of naproxen dose among patients with naproxen-responsive osteoarthritis pain: A randomized, double-blind, placebo-controlled study
59. Comparative inhibitory activity of rofecoxib (Vioxx), meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy female volunteers
60. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
61. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial
62. Selective regulation of cytokine secretion by hydroxychloroquine: Inhibition of interleukin-1 alpha (IL-alpha) and IL-6 in human monocytes and T cells
63. Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks
64. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate
65. Sulphasalazine and male infertility: Reversibility and possible mechanism
66. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis
67. The effectiveness of early treatment with "second-line" antirheumatic drugs
68. Anti-inflammatory drugs and their mechanism of action
69. Methotrexate
70. A trial of etanercept, a recombinant tumor necrosis factor receptor:fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
71. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis
72. 50 Years of antirheumatic therapy: The prognosis of rheumatoid arthritis
73. The mortality of rheumatoid arthritis
74. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs
75. T cells: Pathogenic cells and therapeutic targets in rheumatoid arthritis